Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $1.01 Analyst target: $2.00 Upside: 98.02%
Exicure, Inc., a clinical-stage biotechnology company, develops therapies for neurology, immuno-oncology, inflammatory diseases, and genetic disorders based on its proprietary spherical nucleic acid (SNA) technology. The company is headquartered in Chicago, Illinois.
See the full interactive analysis & chart →Informational only — not investment advice.